Your browser is no longer supported. Please, upgrade your browser.
Instil Bio, Inc.
Index- P/E- EPS (ttm)- Insider Own31.70% Shs Outstand128.74M Perf Week9.25%
Market Cap2.19B Forward P/E- EPS next Y-1.38 Insider Trans3.03% Shs Float111.36M Perf Month10.10%
Income- PEG- EPS next Q-0.20 Inst Own55.80% Short Float3.03% Perf Quarter-
Sales0.14M P/S15839.57 EPS this Y-478.60% Inst Trans- Short Ratio8.16 Perf Half Y-
Book/sh5.17 P/B3.29 EPS next Y-9.60% ROA- Target Price- Perf Year-
Cash/sh4.74 P/C3.59 EPS next 5Y- ROE- 52W Range14.42 - 29.49 Perf YTD-35.70%
Dividend- P/FCF- EPS past 5Y- ROI85.30% 52W High-42.35% Beta-
Dividend %- Quick Ratio35.40 Sales past 5Y- Gross Margin- 52W Low17.89% ATR1.59
Employees150 Current Ratio35.40 Sales Q/Q- Oper. Margin- RSI (14)47.60 Volatility8.69% 10.08%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.78 Prev Close16.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume413.16K Price17.00
Recom2.00 SMA20-1.11% SMA50-9.44% SMA200-13.84% Volume323,991 Change1.49%
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
Jun-01-21 07:00AM  
May-13-21 07:00AM  
Apr-29-21 08:45AM  
Apr-27-21 07:00AM  
Apr-12-21 07:18AM  
Mar-23-21 05:00PM  
Mar-19-21 04:25PM  
Mar-18-21 08:26PM  
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McGaughy R Kent JrDirectorMar 23Buy20.00450,0009,000,0008,478,790Mar 25 05:28 PM
Vivo Capital IX, LLC10% OwnerMar 23Buy20.00300,0006,000,00012,486,787Mar 25 05:32 PM
Crouch BronsonCEO and ChairmanMar 23Buy20.00450,0009,000,00037,980,073Mar 25 04:27 PM